FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer By Ogkologos - April 8, 2026 185 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Adding Gemcitabine to Cisplatin Once per Week Concurrently with IMRT Significantly... April 17, 2024 Diagnosed With Breast Cancer At 24, Her Biggest Fear Wasn’t Death... October 10, 2019 Updated ROAR Analysis Confirms the Benefit of Dabrafenib Plus Trametinib in... January 31, 2022 Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients... April 23, 2025 Load more HOT NEWS Updated Nutrition Facts Label Reflects Science on Diet and Health, including... Life beyond cancer: Improving the long term side effects for children... ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034... Qué deben saber los latinos sobre dejar de fumar y las...
